Safeguarding the gift of life


Monitor to protect a second chance in life.

A patient’s journey does not stop at transplantation - protecting a donated organ or graft from rejection is key to the recipient’s success.

Post-transplant immunosuppressive regimens are essential for preventing organ rejection, but they can also put patients at risk of opportunistic infections.

Amongst others Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and BK Virus (BKV) are associated with significant morbidity and mortality in transplant recipients.These infections can be introduced through the donor organ or reactivated within the recipient after the operation. By proactively and regularly monitoring viral load, care teams can identify possible infections early and better decide on an appropriate management plan.

Harmonization is the key to care

A transplant patient’s journey can span several healthcare facilities, including transplant centres that may be far away from the coordinated care of one’s local specialist. The use of different testing methodologies across various sites makes it difficult to compare viral load results, not to mention that values are not always reported in the World Health Organization (WHO) international standard, where ease of commutability facilitates collaboration between care teams.

See why viral load monitoring and result standardization are important for patient follow-up

Global Head of Clinical Development & Medical Affairs at Roche Diagnostics, Alexandra Valsamakis, discusses the importance of standardized assays.

Standardized results can improve care
Laboratory employee working in molecular laboratory
Monitor to protect a second chance in life

In addition to Roche’s serology tests to safeguard a transplant patient’s journey, the cobas® CMV, cobas® EBV and cobas® BKV tests are critical molecular tests specifically designed to elevate post-transplant monitoring.

These three post-transplant monitoring tests can run from a single patient sample on the fully automated cobas® 5800,  cobas® 6800 and cobas® 8800 Systems, providing laboratories with trusted results quickly in a streamlined workflow. Ready-to-use reagents and controls are calibrated to WHO international standards, ensuring result comparison across healthcare institutions no matter where the tests are run.

With these tests, Roche now has a robust, comprehensive transplant portfolio spanning across serology and molecular diagnostics to enable confident decision making -- all to help clinicians protect a second chance in life.

Explore Roche’s extensive offering to help you answer critical questions related to transplant care
assay overview table

To learn more about our transplant testing solutions, contact us by filling the details below

Form Successfully Submitted!
Thank you for your submission!


  1. Smith TF, Espy MJ, Mandrekar J, Jones MF, Cockerill FR, Patel R. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45(8):1056-1061.